NCT04205409 2025-11-03
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT02719613 2025-06-05
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT03292263 2024-05-07
ASCT With Nivolumab in Patients With Multiple Myeloma
St. Petersburg State Pavlov Medical University
Phase 1/2 Active not recruiting